MorphoSys AG (MOR) Q3 2020 Earnings Conference Call November 12, 2020 8:00 AM ET
Company Participants
Julia Neugebauer - Director of IR
Jean-Paul Kress - CEO
Jens Holstein - CFO
Malte Peters - Chief Research and Development Officer
Roland Wandeler - COO
Conference Call Participants
Geoffrey Porges - SVB Leerink
James Gordon - JPMorgan
Etzer Darout - Guggenheim Securities
Graig Suvannavejh - Goldman Sachs
Shanshan Xu - Berenberg
Operator
So ladies and gentlemen, welcome to the MorphoSys Third Quarter Interim Statement 2020 Conference Call. Please note that for the duration of the presentation all participants will be in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. Please note that we can only take your questions if you have registered the name. [Operator Instructions]
Now I would like to turn the conference over to Dr. Julia Neugebauer. Please go ahead.
Julia Neugebauer
Ladies and gentlemen, good afternoon or good morning. My name is Julia Neugebauer, Director of Investor Relations at MorphoSys, and it's my pleasure to welcome you to our third quarter 2020 financial results and operational update conference call.
Joining me on the call today are Jean-Paul Kress, CEO; Jens Holstein, CFO; Malte Peters, Chief Research and Development Officer; and Roland Wandeler, Chief Operating Officer. A press release was issued yesterday with our third quarter 2020 financial results and business update. This can be found on our website along with the presentation for today's webcast.
Before we begin, I'd like to remind you on Slide 2, that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans, the impact of COVID-19 on our business and expectations for the compounds in our pipeline as well as the
- Read more current MOR analysis and news
- View all earnings call transcripts